SMAD4 Antikörper (AA 100-300)
Kurzübersicht für SMAD4 Antikörper (AA 100-300) (ABIN7869859)
Target
Alle SMAD4 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 100-300
-
Verwendungszweck
- SMAD4 Antibody
-
Aufreinigung
- Protein A/G affinity
-
Immunogen
- A recombinant partial protein sequence (within amino acids 100-300) from the human protein was used as the immunogen for the SMAD4 antibody.
-
Isotyp
- IgG1, lambda
-
-
-
-
Applikationshinweise
- Optimal dilution of the SMAD4 antibody should be determined by the researcher.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Aliquot the SMAD4 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- SMAD4 (SMAD Family Member 4 (SMAD4))
-
Andere Bezeichnung
- SMAD4
-
Hintergrund
- Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4.Upon ligand binding, the receptors of the TGF-beta family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. The lack of SMAD4 expression is present in approximately 80 % of cases of pancreatic adenocarcinoma, but rarely in endometrial (0 %), colorectal (0 %), ovarian (3 %), lung (0 %), breast (2 %) adenocarcinomas, and malignant melanoma (4 %). SMAD4is an important marker for confirming a diagnosis of pancreatic adenocarcinoma.
-
UniProt
- Q13485
-
Pathways
- Zellzyklus, Chromatin Binding, Autophagie
Target
-